Summary Long-circulating (stealth) liposomes coated with polyethylene glycol (PEG), which show reduced uptake by the reticuloendothelial system (RES) and enhanced accumulation in tumours, were used for conjugation to monoclonal antibodies (MAbs) as a drug-targeting device. A MAb (N-12A5) directed against erbB-2 oncoprotein, a functional surface antigen, was used. Amplification and overexpression of the erbB-2 gene product, being unique to malignancy, confer onto this antibody-mediated therapy high tumour specificity. In vitro binding of [3H]cholesteryl ether ([3H]Chol ether) labelled anti-erbB-2 conjugated liposomes to N-87 cells (erbB-2-positive human gastric carcinoma) was compared with the binding of non-targeted liposomes and indicated a 16-fold increase in binding for the targeted liposomes. No difference in binding to OV1063 cells (erbB-2-negative human ovary carcinoma) was observed. These results indicate highly selective binding of antibody-targeted liposomes to erbB-2-overexpressing cells. Despite increased cell binding, doxorubicin (DOX) loaded in anti-erbB-2-conjugated liposomes did not cause increased in vitro cytotoxicity against N-87 cells, suggesting lack of liposome internalisation. In vivo, the critical factor needed to decrease the non-specific RES uptake and prolong the circulation time of antibody-conjugated liposomes is a low protein to phospholipid ratio (< 60 pg pmol-'). Using these optimised liposome preparations loaded with DOX and by monitoring the drug levels and the [3H]Chol ether label, biodistribution studies in nude mice bearing subcutaneous implants of N-87 tumours were carried out. No significant differences in liver and spleen uptake between antibodyconjugated and plain liposomes were observed. Nevertheless, there was no enhancement of tumour liposome levels over plain liposomes. Both liposome preparations considerably enhanced DOX concentration in the tumour compared with free drug administration. Therapeutic experiments with N-87 tumour-bearing nude mice indicated that anti-tumour activity of targeted and non-targeted liposomes was similar, although both preparations had an increased therapeutic efficacy compared with the free drug. These studies suggest that efficacy is dependent on drug delivery to the tumour and that the rate-limiting factor of liposome accumulation in tumours is the liposome extravasation process, irrespective of liposome affinity or targeting to tumour cells.
Recent advances in the design of liposomes have resulted in the development of 'stealth liposomes', small (<100 nm) vesicles, with prolonged circulation time and enhanced tumour localisation properties . These liposomes localise in the tumour extracellular compartment but are not taken up by tumour cells (Gabizon, 1992; Huang et al., 1991; Papahadjopoulos et al., 1991) . To enhance cytotoxic efficacy further, selective delivery of drugs to target cells can be achieved through liposome binding of antibodies that recognize specific determinants on target cells (Ahmad and Allen, 1992; Debs et al., 1987; Peeters et al., 1989) . The cerbB-2 gene product is a membrane glycoprotein of 185 kDa (pl85 HER2) with intrinsic kinase activity. As the product of an activated oncogene, erbB-2 represents an important class of tumour-surface antigens for diagnosis or targeting of monoclonal antibody-mediated therapy (Harris and Mastrangelo, 1989) . Amplification and overexpression of the cerbB-2 gene is shown in many epithelial malignancies, particularly in breast and ovarian carcinomas (15-20% of human carcinomas) (Berchuck et al., 1990; Yonemura et al., 1991) , predicting a poor prognosis (Slamon et al., 1987 (Slamon et al., , 1989 Park et al., 1992) . The phenomenon is unique to malignancy. In normal tissues p185HER2 is expressed only at low levels in certain epithelial cell types (Press et al., 1990) . As the oncoprotein plays a role in cell growth and oncogenesis, blocking it by antibodies may interfere with signal transduction pathways. Moreover, being a membranous overexpressed antigen with ready accessibility and high level of tumour specificity, erbB-2 offers an attractive target for cancer therapy. Here, we describe the development of anti-erbB-2 immunoliposomes as a tumour-targeting vehicle in which the specificity of anti-p185HER2 and the cytotoxic activity of DOX are combined with the pharmacokinetic and drug delivery advantages of liposomes. N12A5 (IgGI) MAb, which has a high binding capacity to erbB-2-overexpressing cells (Stancovski et al., 1991) , was selected for our studies of targeted therapy with doxorubicin-loaded 'stealth liposomes'. N12A5 significantly inhibited the tumour growth of human carcinoma cell line N-87 and mouse fibroblasts transfected with the human gene in nude mice (Hurwitz et al., 1995) , and specifically induced phenotypic differentiation on various cultured breast carcinoma lines (Bacus et al., 1992) . The erbB-2-positive human gastric carcinoma line N-87 (Park et al., 1990) , which grows well in nude mice, was chosen as tumour model.
Materials and methods Liposome preparation
Sources of liposome components were as follows: hydrogenated soybean phosphatidylcholine (HPC) was from Avanti Polar Lipids (Birmingham, AL, USA); cholesterol (Chol) and ac-tocopherol were from Sigma (St Louis, MO, USA); mPEG(2000)/DSPE (polyethylene glycol derivative of distearoylphosphatidyl ethanolamine) and Hz-PEG-DSPE were prepared as described elsewhere (Zalipsky, 1993a) (Zalipsky et al., 1995) .
Cell lines
We chose a human-derived gastric carcinoma, N-87, described previously by Park et al. (1990) , with the ability to develop tumours in nude mice and breast carcinoma BT-474, both with c-erbB-2 overexpression. ZR-75.1 and OV1063 (Horowitz et al., 1985) largest perpendicular diameters of the palpable tumours were measured using calipers, starting on the first treatment day and three times a week thereafter. Tumour volume and approximate weight were estimated by the equation ab2/2 (in mm3 or mg), where a and b are the two largest perpendicular diameters. The tumour volume/weight values were converted in percent change from baseline by the equation V, x 100/ Vo, where V1 is volume measured at time t and V0 is baseline volume. Mice were labelled individually for individual follow-up of tumour growth and tumour weight. Two months after start of treatment, all surviving mice were sacrificed and tumours were dissected carefully and weighed directly.
Results
In vitro binding of immunoliposomes and plain stealth liposomes to erbB-2-positive and -negative cells The binding kinetics of antibody-targeted liposomes and nontargeted liposomes to N-87 cells, erbB-2 overexpressors were studied for 24 h (Figure 1 ). Cell association of liposomes ([3H]Chol ether) and DOX was monitored as described. The binding kinetics curves show that at least 2 h is needed for a measurable association to occur. There was more than a 10-fold increase in liposome binding when antibody was conjugated, as indicated by the [3H]Chol ether marker (Figure la). When DOX was measured, the maximum increase in cell association using antibody-targeted liposomes was 5-fold after 8 h of incubation ( Figure Ib) . After 24 h of incubation, this increased factor of DOX cell association went down to 2.5-fold which was probably a result of the masking effect of DOX leakage from liposomes on the targeting effect. Drug leakage studies from plain liposomes and immunoliposomes, in the presence of 90% plasma at 37°C, did not reveal any significant difference in stability between plain liposomes and immunoliposomes (data not shown). In the following in vitro binding experiments, attachment was monitored after 7 h incubation of liposomes with cells.
Binding of plain, irrelevant Ab or anti-erbB-2 (N12A5) MAb-conjugated liposomes to erbB-2-positive N-87 cells (106) was examined after 7 h incubation at 37°C with 200 nmol of phospholipid per plate (35 mm). Figure 4 , showed no difference between a-erbB-2-coupled liposomes and plain liposomes. IC50 values for plain liposome and immunoliposome DOX were 1.3 x 10-6 M, while the soluble drug was 6-fold more active (2.1 x 10-7 M). In another design of the cytotoxic experiment, N-87 cells were incubated for only 2 h in the presence of DOX (liposomal or free) and then further incubated for 3 days in fresh medium (Figure 4) . IC50 values for plain and immunoliposomes were similar (1.3 x 10' M) and higher than for the free drug by -10-fold (1.1 x 10-6 M). Consistent with this, experiments with BT-474 also demonstrate insignificant differences in IC50 values of DOX in immunoliposomes and plain liposomes (1.1 X 10-6 M and 1.5 x 10-6 M respectively). These results corroborate previous observations indicating that cytotoxicity originates from liposomal drug release in the extracellular fluid and free drug diffusion into the cells (Horowitz et al., 1992 Figure 5 ) Initial pharmacokinetic experiments of antibody-targeted liposomes in mice were done with a-erbB-2-conjugated liposome preparations of relatively high protein/ phospholipid ratio, around 100 jug umol-'. As shown in Figure   5a , high-protein immunoliposomes were cleared from plasma significantly faster than plain liposomes and low-protein immunoliposomes (44 ug ymol-'). As shown in Figure Sb, the differences in plasma DOX clearance rates between targeted and non-targeted liposomes were minimal when a liposome preparation with low protein to lipid ratio was used. DOX and [3H]Chol ether showed a similar clearance rate, suggesting that drug leakage is a minor pathway of clearance. We inferred that low levels of protein conjugated to liposomes are required to maintain stealth qualities of immunoliposomes. Further experiments, shown below, were carried out with these lowprotein immunoliposomes. r-n levels were examined, the peak levels were similar, but it appeared that the drug clearance with immunoliposomes was faster than with plain liposomes. This suggests that immunoliposomes may be incorporated faster than plain liposomes into an intracellular compartment where liposome degradation and drug release occur. Liver uptake was not enhanced when immunoliposomes with low protein to lipid ratio were used.
Tumour (Figure 6b) Figure 6b that the tumour drug levels are much higher when DOX is delivered by plain-liposomes or immunoliposomes than free DOX, indicating a substantial advantage of liposome delivery with respect to tumour drug exposure.
Skin (Figure 6c depot of liposomes in the nude mouse. As the total skin weight in a mouse is about 3 g (twice that of the liver), an uptake of 10% ID g-1 indicates that about 30% of the injected liposomes accumulated in skin.
Therapeutic study As pharmacokinetic studies have shown a close pattern of in vivo distribution for the plain and immunoliposomes, we proceeded by examining whether antibody targeting to tumour cells would result in enhanced therapeutic efficacy of immunoliposomes. Nude mice bearing subcutaneously implanted N-87 carcinoma were treated (i.v.) with 8 mg kg-1 free and liposomal (plain and immuno) DOX on days 15 and 22 after tumour implantation, i.e. at a time when tumour implants became palpable. The therapeutic results given in Table I are the final median tumour weights, after sacrificing the mice 2 months after start of treatment. There was a significant and unequivocally greater tumour-inhibitory effect of liposome-delivered DOX than of free DOX. However, there was no apparent difference in tumour weight when immunoliposome-and plain liposome-treated groups were compared. Figure 7 summarises the relative changes in estimated tumour volume during 60 days of follow-up. As peutic experiment, a significant number of toxic deaths were observed in the group of animals treated with DOX in non-targeted liposomes (12/18 mice died), in contrast to the other experimental groups (1/9 for DOX in immunoliposomes, 1/14 for free DOX, 0/6 for control untreated). All deaths occurred 3-5 weeks after the start of treatment and were preceded by severe weight loss. An additional group of six mice treated with DOX in liposomes lacking the PEG-hydrazide linker (Doxil) showed no signs of toxicity (0/6 deaths) and a level of anti-tumour activity at least as potent as that of the PEG-hydrazide-containing preparation (Table I) . This is consistent with our past experience (Gabizon, 1992; Papahadjopoulos et al., 1991) , which indicates that the dosage of liposomal DOX used in this study is not toxic. These observations suggest that the PEG-hydrazide group in unquenched form (i.e. not protein bound) contributes to the toxicity observed, but not to the anti-tumour activity. 
Discussion
Recent reports have indicated the feasibility of using immunoliposomes for targeted drug delivery to augment the therapeutic efficacy of an encapsulated anti-cancer drug (Ahmad et al., 1993; Emanuel et al., 1996) . These models used DOX in Ab-targeted stealth liposomes, but their relevance to humans is limited as they are based on mouse tumours. We have tried to examine the likelihood that such a strategy could succeed in a human tumour model by targeting liposomes to erbB-2 oncoprotein, a receptor that is stably overexpressed by certain carcinomas and required for the maintenance of aggressive tumour growth (Berchuck et al., 1990 , Slamon et al., 1987 , 1989 . Our aim was to develop stealth immunoliposomes equipped with anti-erbB-2 monoclonal antibodies, to preserve the pharmacokinetic properties of stealth liposomes and to improve tumour drug delivery and anti-tumour activity.
In this study, anti-erbB-2 MAb coupled to stealth liposomes using the Hz-PEG-DSPE linker was found to function as a specific and efficient targeting device in in vitro systems. This is in agreement with other studies using the same coupling system with a different antibody (Allen et al., 1994; Zalipsky et al., 1993b) .
Experiments in biodistribution studies using nude mice bearing N-87 (1996) , in a phase II trial using humanised anti-erbB-2 MAbs, observed accelerated plasma clearance in patients with high plasma levels of extracellular domain of erbB-2 (ECDHER2). Our studies detected minimal differences in plasma clearance rates between immunoliposomes and plain liposomes. Whether this is the outcome of low plasma levels of ECDHER2 or of their minor effect on circulating aerbB-2-targeted liposomes remains to be clarified.
Skin liposome uptake was extremely high for both liposome preparations, a finding consistent with the skin toxicity of a stealth liposomal DOX (Doxil) preparation in humans (Uziely et al., 1995) . High liposome localisation in skin has been reported previously in nude mice (Gabizon et al., 1990; Huang et al., 1993) (Jain, 1989) it is likely that most extravasated vesicles will remain in the tumour site, whether cellbound or not, until they are degraded or cleared by scavenger cells. For complexes of smaller size than liposomes, for which return to the circulation is feasible, binding to an extravascular target cell will be an important determinant of tumour accumulation through decreased washout from the tumour. In fact, a number of soluble MAbs do show a selective enhancement of concentration in the targeted tumour in comparison with irrelevant MAb (Jakowatz et al., 1985) . In line with this, enhanced in vivo efficacy of N12A5 MAb against N-87 tumour (Hurwitz et al., 1995) , and of other anti-erbB-2 antibodies in various tumour models (Bacus et al., 1992; Harwerth et al., 1993) , has been obtained.
A recent report (Park et al., 1995) (1995) . These observations indicate differences in internalisation capacity among the various erbB-2-positive carcinoma cell-lines, or an advantage for Fab' fragments over the bulkier whole IgG in facilitating internalisation. A third possibility is that the lower molar fraction of PEG in the liposomes used by Park et al. (1995) (2% PEG of total phospholipid) may have facilitated internalisation compared with the liposomes used here (7.5% PEG). However, even in the presence of 6.7% PEG, internalisation of liposomes is still possible, as demonstrated by Lee and Low, (1995) , with folate-targeted stealth liposomes and cell lines overexpressing folic acid receptor. These authors also reported that internalisation was accompanied by an increase in the cytotoxicity of liposomal DOX. Whether as a result of the intrinsic properties of the target cells and their receptors, the density of the liposome PEG coating, or the nature and size of the ligand, internalisation may be a necessary step to enhance the cytotoxicity of DOX encapsulated in targeted liposomes, and hence translate targeting into enhanced efficacy. The argument for internalisation in vivo would be that drug released in the tumour intracellular compartment cannot escape from the tumour, while drug released in the interstitial fluid, as in the case of non-targeted liposomes, may still be partially washed out from the tumour and return to circulation.
A positive result of the therapeutic study was the enhanced efficacy of stealth liposomal DOX, with or without targeting antibodies, over free DOX. Similar observations have been made in a number of human xenograft models (Williams et al., 1993; Vaage et al., 1994) . As emphasised in this study, the factors involved in the design of immunoliposomes are complex and unique to this system, and the results may not be extrapolatable to other tumour models, particularly in cases in which the drug becomes bioavailable in the intracellular compartment as a result of immunoliposome internalisation. Our results highlight the serious limitations of the antibody-liposome targeting approach to extravascular tumours. Nevertheless, the advantages of the liposome approach [multivalent binding and delivery of a large drug payload; the availability of long-circulating liposomes; an ever-increasing variety of ligand-coupling techniques; and the possibility of aiming at alternative targets such as the tumour microvasculature (Burrows and Thorpe, 1993) 
